ABO 101 - Arbor Biotechnologies
Alternative Names: ABO-101 - Arbor BiotechnologiesLatest Information Update: 30 Jun 2026
At a glance
- Originator Arbor Biotechnologies
- Class Gene therapies
- Mechanism of Action Glycolate oxidase expression modulators
-
Orphan Drug Status
Yes - Primary hyperoxaluria; Primary hyperoxaluria type 1
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Primary hyperoxaluria type 1
Most Recent Events
- 25 Jun 2026 ABO 101 - Arbor Biotechnologies receives Orphan Drug status for Primary hyperoxaluria in European Union
- 06 Oct 2025 Chiesi Farmaceutici and Arbor Biotechnologies enters into an exclusive global collaboration and license agreement for ABO 101 for the treatment of Primary Hyperoxaluria Type 1 (PH1)
- 16 Jun 2025 Phase-I/II clinical trials in Primary hyperoxaluria type 1 (In adolescents, In children, In adults) in United Kingdom (IV) (NCT06839235)